10-Q: Codexis Q3 2025: Revenue Declines, Net Loss Narrows Amid Strategic Shift

Codexis reports a decrease in total revenues for Q3 and YTD 2025, alongside a narrower net loss, as it focuses on its ECO Synthesis platform and implements a workforce reduction.

Summary

• Total revenues decreased by $4.2 million (33%) to $8.6 million for the three months ended September 30, 2025, compared to the same period in 2024.
• Total revenues decreased by $6.4 million (17%) to $31.5 million for the nine months ended September 30, 2025, compared to the same period in 2024.
• Product revenue decreased by $4.4 million (39%) to $6.8 million for Q3 2025 and by $6.7 million (25%) to $20.2 million for the nine months ended September 30, 2025.
• Research and development revenue increased by $0.1 million (7%) to $1.8 million for Q3 2025 and by $0.3 million (3%) to $11.2 million for the nine months ended September 30, 2025.
• Net loss for Q3 2025 was $19.6 million ($0.22 per basic and diluted share), compared to a net loss of $20.6 million ($0.29 per share) for Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $53.6 million ($0.62 per share), compared to a net loss of $54.9 million ($0.78 per share) for the same period in 2024.
• Product gross margin improved to 64% for both the three and nine months ended September 30, 2025, up from 61% and 53% respectively in the corresponding periods in 2024, primarily due to a shift in sales toward more profitable products.
• Cash, cash equivalents, and short-term investments totaled $58.7 million as of September 30, 2025, a decrease from $90.3 million as of September 30, 2024.
• Net cash used in operating activities increased to $39.5 million for the nine months ended September 30, 2025, from $32.9 million in the prior year.
• The company entered into an enzyme supply assurance agreement with Merck Sharp & Dohme LLC (Merck) in October 2025, entitling it to a one-time non-refundable payment of $37.8 million, expected in Q4 2025.
• A workforce reduction of approximately 24% was announced in November 2025, expected to result in an additional expense of approximately $3.5 million in Q4 2025 for post-employment benefits and related tax costs.

Sentiment

Score: 4

Explanation: While the company reported a narrower net loss and improved product gross margins, the substantial decline in total revenues and increased cash burn from operations indicate ongoing financial challenges. The strategic focus on the ECO Synthesis platform and the significant one-time payment from Merck are positive developments, but the announced workforce reduction highlights the need for operational streamlining. The overall financial picture is challenging, but with some positive operational and strategic shifts.

Positives

• Net loss narrowed for both the three months ($19.6 million vs. $20.6 million) and nine months ($53.6 million vs. $54.9 million) ended September 30, 2025, primarily due to lower costs and operating expenses.
• Product gross margin significantly improved to 64% for both Q3 and YTD 2025, up from 61% and 53% respectively in 2024, driven by a shift towards more profitable products.
• Research and development revenue increased by 7% in Q3 2025 and 3% year-to-date, indicating growth from existing collaboration agreements and milestone recognition.
• Secured a $37.8 million one-time non-refundable payment from Merck in October 2025 for an enzyme supply assurance agreement, which will enhance liquidity in Q4 2025.
• Successfully funded the second tranche of $10.0 million from the Innovatus Loan in June 2025 upon achieving certain financial milestones, bringing the total loan to $40.0 million.
• Completed the build-out of the ECO Synthesis Innovation Lab by the end of 2024, a facility capable of synthesizing gram-scale quantities of siRNA for pre-clinical testing.
• Presented positive data at TIDES EU and TIDES U.S. conferences demonstrating the ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and controlling stereochemistry.
• Three Contract Development and Manufacturing Organizations (CDMO) validated the transferability of the company's ligation processes to their in-house facilities.

Negatives

• Total revenues decreased significantly by 33% in Q3 2025 and 17% year-to-date compared to the prior year, indicating a contraction in overall sales.
• Product revenue, the largest component of total revenue, declined by 39% in Q3 2025 and 25% year-to-date, primarily due to variability in customer manufacturing schedules and clinical trial progression.
• Cash, cash equivalents, and short-term investments decreased from $90.3 million as of September 30, 2024, to $58.7 million as of September 30, 2025.
• Net cash used in operating activities increased by $6.5 million to $39.5 million for the nine months ended September 30, 2025, reflecting higher cash burn.
• A workforce reduction of approximately 24% was announced in November 2025, which will incur an estimated $3.5 million in expenses in Q4 2025.
• Interest income decreased by 25% in Q3 2025 and 28% year-to-date due to lower average cash, cash equivalents, and short-term investment balances.
• The accumulated deficit increased to $616.4 million as of September 30, 2025, from $562.8 million as of December 31, 2024, indicating continued historical losses.

Risks

• The company has a history of net losses and may not achieve or maintain profitability.
• Therapeutics development programs are highly regulated and expensive, and enzyme products are complex and subject to quality control requirements, making regulatory approval for customer products highly uncertain.
• The FDA or other regulators may disagree with the company's assessment that its products are exempt from FDCA requirements, potentially subjecting them to more onerous regulations like cGMP.
• The company is dependent on a limited number of customers, increasing the risk of quarterly fluctuations in revenues and adverse effects from the loss or reduction of business from significant customers.
• Some product supply agreements with customers have finite durations, may not be extended or renewed, and generally do not require the customer to purchase any particular quantity of products.
• Demand for products depends in part on customers' research and development and the clinical and market success of their products, which can be harmed by reduced spending or unsuccessful activities, influenced by general market and economic conditions.
• Inability to develop and commercialize new products for the pharmaceutical, biotherapeutics, diagnostics, and life science tools markets could harm the business and prospects.
• A reduction or delay in government funding of research and development for customers may adversely affect the business.
• Termination or expiration of patent protection for customer APIs and any resulting generic competition may materially and adversely affect revenues.
• The services and offerings provided are highly complex, and problems in providing services or support could harm the business.
• Productivity issues or higher-than-expected costs at facilities could result in material and adverse impacts on financial condition and results of operations.
• The company is dependent on a limited number of third-party contract manufacturers for large-scale enzyme production; efforts to qualify new manufacturers may not be successful, leading to supply limitations.
• Dependence on collaborators; failure to successfully manage these relationships could prevent product development and commercialization, and hinder profitability.
• Significant resources have been invested in enzymatic nucleic acid synthesis (ECO Synthesis), which is based on novel and largely unproven technologies; failure to validate performance at scale, demonstrate regulatory acceptance, or overcome other challenges could impede customer adoption and revenues.
• As a result of its strategic shift and refined focus on certain programs, the company may fail to capitalize on other opportunities that may be more profitable or have a greater likelihood of success.
• Given the change in strategic direction, the company may receive limited revenue or no future value from certain existing license agreements.
• The timing of customer orders and related product revenue recognition is unpredictable and may cause operating results to vary significantly from quarter to quarter, which could adversely affect the stock price.
• The company uses hazardous materials and must comply with environmental laws and regulations; claims relating to improper handling or noncompliance could be time-consuming and costly.
• The company may need additional capital in the future to expand its business, and existing capital resources may be utilized sooner than expected.
• Even if customers obtain regulatory approval for products utilizing the company's enzymes, such products will remain subject to ongoing regulatory requirements, which may result in significant additional expense.
• Failure to comply with certain healthcare laws, including fraud and abuse laws, could lead to substantial penalties.
• Efforts to prosecute, maintain, protect, and defend intellectual property rights may not be successful.
• Third parties may claim infringement, violation, or misappropriation of their intellectual property rights, which may subject the company to costly and time-consuming litigation.
• Involvement in lawsuits to protect or enforce intellectual property rights could be expensive, time-consuming, and unsuccessful.
• If biocatalysts or the genes that code for them are stolen, misappropriated, or reverse engineered, others could use them to produce competing products.
• Anti-takeover provisions in the certificate of incorporation and bylaws and under Delaware law could delay or prevent an acquisition.
• Market and economic conditions, including inflation, energy costs, geopolitical issues, and financial market instability, may negatively impact the business, financial condition, and share price.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect the business.
• Business interruptions resulting from disasters or other disturbances (e.g., earthquakes, wildfires, public health emergencies) could delay product development and disrupt sales.
• Dependence on information technology systems, infrastructure, and data; any failure, security breach, or loss of data could harm the business and expose it to liability, intensified by the accessibility of AI tools.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws (e.g., HIPAA, CCPA, CPRA, GDPR) could adversely affect the business.
• Evolving expectations around corporate responsibility practices, specifically related to environmental, social, and governance (ESG) matters, may expose the company to reputational and other risks.

Future Outlook

The company expects to manufacture GLP-grade siRNA for customers in its Innovation Lab under development services contracts in 2025. In the near term, it anticipates entering a partnership with a large-scale CDMO to use its ECO Synthesis platform for GMP-grade siRNA drug substance manufacturing. The company plans to expand its enzymatic tools and process offerings to address market needs for scalable and sustainable RNAi manufacturing. It believes existing cash and cash equivalents, short-term investments, and future revenues will provide adequate funds for planned ongoing operations, capital expenditures, and working capital requirements for at least the next 12 months. However, it may need additional capital if current plans and assumptions change, and may choose to seek additional capital through equity offerings, debt financings, or strategic collaborations.

Management Comments

• We are a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and we leverage our proprietary CodeEvolver directed evolution technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins.
• In 2025, we expect to manufacture good laboratory practice (GLP)-grade siRNA for customers in our Innovation Lab under development services contracts model, and in the near term we anticipate entering a partnership with a large-scale CDMO to use our ECO Synthesis platform of enzymatic tools and processes to synthesize good manufacturing practices (GMP)-grade siRNA drug substance for our customers.
• We expect to expand our enzymatic tools and process offerings as we further enhance the ECO Synthesis platform to address the overall market needs for scalable and sustainable RNAi manufacturing.
• We believe that our existing cash and cash equivalents, combined with our future expectations for product revenues, research and development revenue, and expense management will provide adequate funds for planned ongoing operations, capital expenditures and working capital requirements for at least the next 12 months.

Industry Context

Codexis operates in the rapidly evolving biotechnology and pharmaceutical manufacturing sectors, focusing on enzymatic solutions. Its strategic shift towards ECO Synthesis for RNAi therapeutics aligns with the growing demand for efficient and scalable manufacturing in the biotherapeutics space. The industry is characterized by intense competition from both traditional chemical synthesis methods (phosphoramidite chemistry) and other enzymatic approaches, as well as large industrial enzyme companies and CDMOs. The company's efforts to partner with CDMOs for GMP-grade siRNA production reflect a common industry strategy to scale novel technologies and meet regulatory standards. The workforce reduction indicates a strategic streamlining to focus resources on core, high-potential platforms like ECO Synthesis, a trend seen in companies optimizing operations amidst R&D investments and seeking efficiency.

Comparison to Industry Standards

• The ECO Synthesis manufacturing platform is presented as offering improvements over the current industry standard, solid-phase oligonucleotide synthesis using phosphoramidite chemistry, by potentially reducing required infrastructure investments, mitigating batch size limitations, and addressing waste disposal challenges.
• The company's data demonstrated that full-length oligos of equal quality and yields were obtained using enzymatic ligation with its dsRNA ligase, whether fragments were made with enzymes or by traditional phosphoramidite chemistry, suggesting competitive performance against established methods.
• Three presentations from Contract Development and Manufacturing Organizations (CDMOs) validated the transferability of Codexis' ligation processes to their in-house facilities, indicating industry acceptance and potential for broader adoption of its enzymatic tools.
• Primary competitors in the performance enzymes for pharmaceutical products markets include large industrial enzyme companies such as Novozymes and DuPont, as well as subsidiaries of larger contract research/CMOs like DSM-Firmenich AG, Cambrex Corporation, Lonza Group, WuXi STA, and Almac Group Ltd.
• Competitors in the enzyme customization and optimization area include smaller companies such as BRAIN Biotech AG, Arzeda Corp., and c-LEcta GmbH.
• Primary competitors in the RNAi therapeutics manufacturing space using phosphoramidite chemistry include CDMOs like Agilent Technologies, which has made significant capital investments to expand their capabilities.
• Early-stage competitors pursuing fully enzymatic RNA manufacturing include EnPlusOne Biosciences, a private startup company, and a UK-based consortium led by CPI, including The University of Manchester, AstraZeneca plc, and Novartis.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material pending litigation or other material legal proceedings that management believes could have a material adverse effect on its financial statements.

Stakeholder Impact

• Shareholders: Potential for future dilution from equity offerings, impact of anti-takeover provisions, and fluctuations in stock price due to varying operating results. The narrowing net loss and Merck payment could be seen positively, while revenue decline and increased cash burn are concerns.
• Employees: A workforce reduction of approximately 24% was announced in November 2025, leading to post-employment benefits and related expenses for impacted individuals. This indicates a strategic streamlining of the organization.
• Customers: Variability in manufacturing schedules and clinical trial progression impacted order volumes. New GLP-grade siRNA manufacturing services and anticipated GMP-grade production through CDMO partnerships could offer enhanced capabilities and supply for customers.
• Creditors (Innovatus): The Innovatus Loan is secured by substantially all company assets, and restrictive covenants limit business activities. Failure to comply could lead to acceleration of debt maturity and foreclosure, posing a risk to the company's financial stability.
• Suppliers/Contract Manufacturers: Dependence on a limited number of third-party contract manufacturers for large-scale enzyme production poses risks of supply limitations if efforts to qualify new manufacturers are unsuccessful, potentially impacting the supply chain.

Next Steps

• Manufacture GLP-grade siRNA for customers in the Innovation Lab under development services contracts in 2025.
• Anticipate entering a partnership with a large-scale CDMO to use the ECO Synthesis platform for GMP-grade siRNA drug substance manufacturing in the near term.
• Expand enzymatic tools and process offerings to further enhance the ECO Synthesis platform.
• Receive a one-time non-refundable payment of $37.8 million from Merck during the fourth quarter of 2025.
• Recognize an additional expense of approximately $3.5 million in Q4 2025 for post-employment benefits and related tax costs due to the workforce reduction.
• Substantially complete the workforce reduction by January 2026.
• Continue to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Monitor SEC rulemaking activity and evaluate potential effects of ASU No. 2023-06 (Disclosure Improvements).
• Evaluate the effects of ASU No. 2024-03 (Expense Disaggregation Disclosures) on consolidated financial statements and related disclosures.

Key Dates

Recommendation

The company faces significant revenue declines and continued operating losses, indicating ongoing challenges in its core business. However, the improved gross margins, strategic focus on the promising ECO Synthesis platform, and the substantial one-time payment from Merck provide some positive momentum and liquidity. The announced workforce reduction, while incurring short-term costs, aims to streamline operations and focus resources, which could be beneficial long-term. Given the mixed signals—revenue contraction versus strategic realignment and a cash infusion—a 'hold' recommendation is appropriate. Investors should monitor the execution of the ECO Synthesis strategy, the impact of the workforce reduction on future expenses, and the company's ability to secure new partnerships and achieve profitability. The stock is speculative due to the unproven nature of the ECO Synthesis platform at commercial scale and dependence on a limited customer base.

Keywords

Enzymatic solutions, Biocatalysis, ECO Synthesis, RNAi therapeutics, Enzyme engineering, Pharmaceutical manufacturing, Biotherapeutics, Life science tools, CodeEvolver platform, siRNA synthesis, Biotechnology, SEC filing, 10-Q, Financial results, Workforce reduction